Glycolytic and fatty acid oxidation genes affect the treatment and prognosis of liver cancer

Figure 8 Prediction of the efficacy of immune checkpoint blockade therapy and chemotherapy drugs in The Cancer Genome Atlas datasets. A: Distribution of Tumour Immune Dysfunction and Exclusion scores in high-risk subtype of liver hepatocellular carcinoma vs low-risk subtype of liver hepatocellular carcinoma; B: Box plot shows samples with response to immune checkpoint blockade therapy; C: Half-maximum inhibitory concentration of clinical anti-cancer drugs forecasted by Genomics of Drug Sensitivity in Cancer.